DALLAS, Oct. 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today confirmed the company is pursuing the development of Over-The-Counter (OTC) and prescription CBD treatments. The company yesterday released an update on its latest Cannabis Extract Biopharmaceutical developments. The information from yesterday’s release to include the specifics on the OTC and prescription CBD treatments is contained here in today’s release.
KALY has implemented a sustainable strategy to develop cannabis extracts from its US Patented Cannabis Extraction Process to treat a variety of specific health issues. In light of the long-term commitment to the biopharmaceutical development process and the corresponding requirement for continuous fund raising through the process, KALY has implemented a parallel business strategy to more immediately monetize its patented intellectual property through consumer applications of its technology. KALY has issued a limited license of its patented process to Puration, Inc. (PURA) for the infusion of cannabis extracts into beverages. KALY has also developed and is selling its own line of CBD infused candies under the brand name Hemp4mula. The candies are for sale on North American Cannabis Holdings (USMJ) eCommerce site, www.usmj.com. KALY has also signed direct cannabis extraction contracts with hemp farming operations with a total value so far of $15 million. KALY management recently announced an anticipated jump in revenue in Q4 2019 related to the company’s CBD extraction contracts with hemp farming operations currently underway now that the hemp harvest season is in full swing. As KALY’s consumer focused business proceeds and has more regular news events than the biopharmaceutical business, KALY management has committed to providing regular updates, like the one today, on the company’s biopharmaceutical business.
Cannabis Extract Biopharmaceutical Developments Update
The cannabis sector is rich with a variety of business operations pursuing the consumer sector. KALY stands out as one of the very few with patented technology. KALY differentiates itself even further with its pursuit of the biopharmaceutical sector. It is important for KALY to periodically issue updates on its otherwise behind the scenes biopharmaceutical business to remind investors that it is in fact our biopharmaceutical business that is the underpinning of the recently published analyst recommendations.
In the fourth quarter of last year, 2018, KALY acquired NCMB. In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions. KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. The market for COPD treatment is anticipated to reach $14 billion by 2025.
In addition to KALY’s ongoing efforts to develop prescription therapies, KALY has initiated a program to certify its proprietary CBD extracts derived from KALY’s U.S. Patented Extraction Process as an Over-The-Counter (OTC) drug under the requirements prescribed by the U.S. Food and Drug Administration.
Since the last biopharmaceuticals strategy update, KALY has made substantial strides. KALY has since engaged with a major university to initiate a next round of evaluations and testing of its COPD treatment. The university program is anticipated to kickoff soon and the company plans to issue periodic updates as the program proceeds.
KALY has also made recent progress in advancing the development of its other treatments. The advances have been made possible by new partnerships. Announcements about the new partnerships are coming soon.
To stay abreast of the latest developments and learn more about the company visit https://www.kali-extracts.com/.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.